Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective
Alimentary Pharmacology & Therapeutics · 2025-05 · 61 (9) · 1467-1478
DOI: 10.1111/apt.70020 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2025-02-18. Written by Zobair M Younossi and 17 co-authors. Institution: Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolic Diseases. Cited 66 times so far (Crossref); 99 references. Funded by: ProSciento Inc., USA.
Abstract (original language)
Background
The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well‐being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non‐invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD‐related problem.
Aim
The aim of this article was to summarise the global burden of MASLD from the payer's perspective.
Methods
We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient‐reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively.
Conclusion
The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. Trial Registration: NCT06309992
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
- The Global NASH Council, Washington, DC, USA.
- Center for Disease Analysis Foundation, Lafayette, Colorado, USA.
- RA Capital Management, L.P., Boston, Massachusetts, USA.
- Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic Minnesota, Rochester, Minnesota, USA.
ORCID profiles: Quentin M Anstee, Kenneth Cusi, Jeffrey V Lazarus, Detlef Schuppan, Manuel Romero-Gómez, Vincent Wai-Sun Wong, Arun J Sanyal, Rohit Loomba
Funding
- ProSciento Inc., USA
Cite
APA
Younossi, Z. M., Razavi, H., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., Romero-Gómez, M., Schattenberg, J. M., Vos, M. B., Wong, V. W., Ratziu, V., Hompesch, M., Sanyal, A. J., & Loomba, R. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics, 61(9), 1467-1478. https://doi.org/10.1111/apt.70020
Vancouver
Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 2025;61(9):1467-1478. doi:10.1111/apt.70020
BibTeX
@article{Younossi2025,
author = {Younossi, Zobair M and Razavi, Homie and Sherman, Michael and Allen, Alina M and Anstee, Quentin M and Cusi, Kenneth and Friedman, Scott L and Lawitz, Eric and Lazarus, Jeffrey V and Schuppan, Detlef and Romero-Gómez, Manuel and Schattenberg, Jörn M and Vos, Miriam B and Wong, Vincent Wai-Sun and Ratziu, Vlad and Hompesch, Marcus and Sanyal, Arun J and Loomba, Rohit},
title = {Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {9},
pages = {1467--1478},
doi = {10.1111/apt.70020}
}
EUVIMED